The abstract is read at the publisher; the summary is JClub's.
The multi-cancer early detection (MCED) test in the PATHFINDER 2 study achieved a cancer detection rate of 0.54% among participants aged 50 or older, with a CSO prediction accuracy of 91.3%.
- Why it matters: Early cancer detection is crucial for improving survival, but many cancer types lack effective screening methods, creating a need for reliable blood-based tests that can identify multiple cancers early.
- What they did: The study evaluated performance metrics—including cancer detection rate, predictive values, sensitivity, specificity, and CSO prediction accuracy—in over 32,000 participants, alongside safety assessments over 12 months, with no hypothesis testing performed.
- The result: The MCED test demonstrated high negative predictive value (99.2%) and specificity (99.64%), with only 0.6% of participants undergoing invasive procedures after positive results, and no serious adverse events reported, supporting its potential safety and performance in screening populations.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.
- 1 cited this week
- Open access